No content results match your keyword.
Content
You have successfully logged out.
Not registered yet?
No content results match your keyword.
Content
No product results match your keyword.
Products
Dosage Error in Pediatrics
Avoiding medication errors is, of course, important in the entire field of medicine. In neonates, infants, and children, however, it is absolutely crucial as their physiological reserve is so much smaller than in adults: An improper dose that might pass unnoticed or results in more side effects in an adult can quickly become life-threatening in our youngest patients – and that includes underdosing, the often neglected stepchild of dosage errors.
One factor that plays a major role in underdosing is what literature refers to as “dead volume” or “residual volume”. These terms mean the same thing, namely, the (variable) volume of a prescribed drug that remains in the infusion system after the infusion has ended. Without taking measures to ensure that this volume is infused as well, the patient will not receive their full prescribed medication dose – with potentially adverse consequences such as inefficacy or resistance. Evidence has shown that the best way to avoid this from happening is to choose extension lines with a small diameter and the smallest syringe size possible, and to use infusion sets that can be flushed at the end of the infusion.
Be it overdosing or underdosing, one thing remains the same: In pediatrics, there simply is no room for error.
A dosage error is the most frequent type of medication error in children.1, 2
A medication error can occur during the prescription, dispensing, or administration of a drug. By definition, it is considered an error regardless of whether or not it leads to adverse consequences.3 4
Pediatrics is seen as an area particularly prone to medication errors: Children, toddlers and babies famously come in all shapes and sizes and are, therefore, dosed on an individual basis using factors such as age, weight, and surface area, which requires repeated manipulations and dilutions. In neonates especially, significant weight changes over time necessitate frequent re-calculations5. In addition, healthcare staff may be unfamiliar with the treatment of this age group, and appropriate dosage forms may not always be available.6
One of the most frequent causes of underdosing is the incomplete delivery of the container content:
In 50 mL infusions, up to 32.2% of the active compound remains in the IV line.8, 9
50 mL IV antibiotics may be underdosed by up to 50%.10
In pediatrics and neonatology, most errors occur during dispensing and administration; dosing errors, i.e., overdosing or underdosing, are the most frequently reported error type.1, 2
As mentioned in the introduction, underdosing can be due to dead volume.11 The volume may vary greatly depending on the type of infusion system used, the length and diameters of the infusion tubing and the application of distributors (e.g., Y-connectors). This can cause significant delays in drug administration, especially in small dosages and when using slow, concentrated infusions.11 Experts have warned that the significance of dead volumes in infusion bottles and sets is not yet widely appreciated.12
How much of the drug is lost depends on various factors, including:
In addition, there is the issue of drug delivery: Slow-flowing, small infusion lines, such as in neonatal care, can considerably delay the active compound reaching the patient.13 In one experimental study, it took one and a half minutes for the medication to reach the simulated infant through a catheter alone; with extension tubing, it took seven minutes.11
The health consequences of underdosing not only depend on the amount of the active compound lost to the patient but also on the substance itself: In drugs with a broad therapeutic index, even the loss of around 10% of the active substance can be without consequence. But in drugs with a narrow therapeutic window, underdosing may well lead to serious adverse consequences, including insufficient treatment, therapy failure, disease progression, and the development of resistance to antibiotics and cytostatic agents.12
Dead volumes in IV systems may also have grave consequences if the following infusion has a higher flow rate, as this would result in the residue being administered as a bolus. If the following infusion contains a drug incompatible with the previous infusion, precipitation may occur.14
Studies specifically analyzing the financial consequences of underdosing are, to our best knowledge, still lacking. However, it stands to reason that the clinical sequelae mentioned above – insufficient treatment or treatment failure, development of resistances – will also increase costs by negatively impacting a patient’s need for additional or longer therapy and extending their length of hospital stay. tive substance applicable without causing a health risk).
Infusion sets to minimize dead volume
Use a shorter secondary administration set
Use micro droppers to ensure precise application of tiny volumes
Include a sufficient flushing procedure with flushing sets
Be aware that higher infusion volumes should, in principle, only be used in patients with no restriction on the volume of liquid. They are impractical in, e.g., critically ill or pediatric patients due to the risk of volume overload.14
Pediatrics & Neonatology
[1] Miller RM et al, Qual Saf Health Care 2007;16:116-126.
[2] Cowley E et al, Curr Ther Res Clin Ex 2001, doi: 10.1016/W0011-393(01)80069-2.
[3] James JT, J Patient Saf 2013;9:122-128.
[4] Valentin A et al, Intensive Care Med 2006;32:1591-1598.
[5] Conroy S et al, Drug Saf 2007;30:1111-1125.
[6] Neuspiel DR et al, Health Serv Insights 2013;6:47-59.
[7] Zakharov S et al, Ups J Med Sci 2012;117:309-317.
[8] Plagge H et al, Pharma Publishing and Media Europe 2010;16:31-37.
[9] Federal Institute of Drugs and Medicinal Devices 2015; The Forgotten Residue: Dead Volumes of Short-term Infusions, Pub. No. 2.
[11] Gregerson BG et al, Proc Bayl Univ Med Cent 2018;31(2):168-170.
[12] Lilienthal N, The Forgotten Residue, Federal Institute of Drugs and Medicinal Devices (BfArM).
[13] Lala AC et al, Journal of Paediatrics and Child Health 2015;51:478-481.
[14] Mitteilung Deutsches Ärzteblatt 2017;114:40,1835-1836.
[15] Conn R et al, the Pharmaceutical Journal 2018, https://pharmaceutical-journal.com/article/ld/prescribing-errors-in-children-why-they-happen-and-how-to-prevent-them.
[16] Physician Insurers Association of America. Medication Errors Symposium White Papers. Washington, DC: Physician Insurers Association of America; 2000.
[17] Kohn L et al, (2000) To Err Is Human: Building a Safer Health System. Washington, DC: Committee on Quality of Health Care in America, Institute of Medicine. National Academies Press, ISBN: 9780309068376.
[18] Walsh EK et al, Pharmacoepidemiol Drug Saf 2017;26(5):481-497.
[19] Pinilla J et al, The European Journal of Health Economics 7(1):66-71.
[20] WHO (2013): Hospital Care for Children. Guidelines for the Management of Common Childhood Illnesses. 2nd edition, Geneva.
Your feedback matters! Participate in our customer survey to help us enhance our website, products and services. Thank you for your support!